European Archives - Page 514 of 1164 - European Medical Journal

A pandemic response in 100 days

This infographic looks at the mission to make an effective vaccine against any virus in just 100 days and explores the diseases that are re-emerging that could be combatted with an expedited approach.

Current and future management of EGFR-positive NSCLC

This educational webinar has been organised and funded by The Janssen Pharmaceutical Companies of Johnson & Johnson. The content

Access win for HIV patients in sub-Saharan Africa

The injectable HIV treatment cabotegravir is set to become more widely available in sub-Saharan Africa following a new licensing agreement.

Unpacking the Immune System

This week, Peter Arkwright, Senior Lecturer in Paediatric Allergy and Immunology, Lydia Becker Institute of Immunology and Inflammation, University of Manchester, UK, joins Evgenia to speak about the prevalence of allergy and the challenges surrounding immune disease in children.

The Role of Patient Empowerment as a Key Component of Effective Multidisciplinary Cancer Care

This podcast, funded by Astrazeneca, enhances a multidisciplinary team approach in the management of patients with cancer.

The Sunshine Rule: 5 years on

The Sunshine Rule swept away the clouds that cast shade over the pharmaceutical industry’s interactions with its customers, but what has been its impact five years on?

Neoadjuvant Treatments in Breast Cancer

This webinar covers the current data and ongoing research on neoadjuvant treatments for different breast cancer subtypes.

Treating Non-melanoma Skin Cancer with the Non-invasive, Single Session Approach Rhenium-SCT

This podcast episode delves into alternative treatment for non-melanoma skin cancer using Rhenium-SCT. Listen now!

Sanofi lights ‘Beacon of Hope’ in race for greater diversity

Sanofi has joined the ‘Beacon of Hope’ programme – a Novartis initiative seeking to address racial inequality in clinical trials, health and education and to create greater diversity across R&D structures.

Next Step in Incretin-Based Therapy: From Single to Dual Agonism

The incretin effect, an augmented prandial insulin response, is mediated mostly by the hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), which are released from the intestines after meals.